Архиви на јавното здравје

Том. 14 Бр. 2 (2022): Архиви на јавно здравје
Јавно здравје

Ставoви и практики за Хуман Папиломавирус, вакцина за Хуман Папиломавирус и поврзани фактори меѓу населението во Република Косово

OnlineFirst (English) pdf 34-45 (English)
  • Ернад Косуми,
  • Милаим Косуми,
  • Моме Спасовски
Ернад Косуми
Универзитет Св. Кирил и Методиј во Скопје, Медицински факултет, Докторски студии по јавно здравје, Република Северна Македонија
Милаим Косуми
„Универзитет за медицина“ Тирана, Факултет за технички медицински науки, Тирана, Албанија
Моме Спасовски
Медицински факултет, Универзитет Св. Кирил и Методиј во Скопје; Институт за социјална медицина, Република Северна Македонија
ДОИ: https://doi.org/10.3889/aph.2022.6067

Објавено 2022-12-30

Клучни зборови

  • хуман папиломавирус,
  • рак,
  • Република Косово,
  • став,
  • пракса

Како да се цитира

1.
Косуми Е, Косуми М, Спасовски М. Ставoви и практики за Хуман Папиломавирус, вакцина за Хуман Папиломавирус и поврзани фактори меѓу населението во Република Косово. Arch Pub Health [Internet]. 2022 Dec. 30 [cited 2024 Jul. 16];14(2):34-45. Available from: https://id-press.eu/aph/article/view/6067

Авторско право(c) 2022 Ernad Kosumi, Milaim Kosumi, Mome Spasovski

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Апстракт

Приближно 50-80% од сексуално активните жени се изложени на барем една варијанта на ХПВ во текот на нивниот живот. Врз основа на годишниот извештај на Националниот институт за јавно здравје на Косово за 2015 година, откриени се 68 нови случаи на рак на грлото на матката. Целта на студијата беше да се истражи ставот и практиката во однос на инфекциите со хуман папиломавирус (ХПВ) и вакцината против хуманиот папилома вирус кај населението на Република Косово. Материјал и методи: Спроведена е студија на пресек за да се процени знаењето за ХПВ инфекциите кај популацијата на возраст од 18 до 35+ години. Студијата е спроведена во периодот јуни 2021 година до август 2021 година. Примерокот опфати 500 учесници. Прашалникот беше анонимен, а учесниците можеа слободно да го прекинат своето учество во секое време, без да го пополнат прашалникот. Резултати: Во однос на тврдењето „ХПВ вакцината е безбедна“повеќe од половина од испитаниците, односно 58,6% се изјасниле дека не знаат, 33,4% од испитаниците се согласуваат, 6,0% дале неточен одговор/ не се согласуваат, а 2,0% не одговориле. Процентуалната разлика помеѓу непознатите и точните одговори е статистички значајна за p<0,05. Заклучок: Оваа студија покажа дека односот кон ХПВ вакцината кај жителите на Република Косово е низок до умерен. ХПВ вакцините треба да бидат вклучени во националните програми за имунизација, бидејќи сèуште не постои воспоставена национална програма за вакцинација против ХПВ.

OnlineFirst (English) pdf 34-45 (English)

Downloads

Download data is not yet available.

Референци

  1. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30: F12–F23. DOI: https://doi.org/10.1016/j.vaccine.2012.07.055
  2. Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer 2015;136: 2752–2760. DOI: https://doi.org/10.1002/ijc.29082
  3. Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijgert JH. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010;10: 862–874. DOI: https://doi.org/10.1016/S1473-3099(10)70190-0
  4. Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, et al. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ. 2012;344: e4168. DOI: https://doi.org/10.1136/bmj.e4168
  5. Roset Bahmanyar E, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, et al. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol 2012;127: 440–450. DOI: https://doi.org/10.1016/j.ygyno.2012.08.033
  6. Jing L, Zhong X, Zhong Z, Huang W, Liu Y, Yang G, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women. Sex Transm Dis 2014;41: 732–738. DOI: https://doi.org/10.1097/OLQ.0000000000000201
  7. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix] Drugs. 2008; 68:359–72. DOI: https://doi.org/10.2165/00003495-200868030-00007
  8. Moscicki A, Schiffmanb M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(Suppl. 3): S42–51. DOI: https://doi.org/10.1016/j.vaccine.2006.06.018
  9. WHO. Report of the consultation on human papillomavirus vaccines. WHO Immunization, Vaccine and Biologicals, Geneva. Available at: www.who.int/vaccines-document/2005. Accessed on: 15th June 2013.
  10. Joseph ET, Myriam CD, Lyndsay AR, Maaike D, Eduardo LF. Epidemiology and burden of HPV infection and related disease: Implication for prevention strategies. Preventive Medicine 2011; 53:12-21. DOI: https://doi.org/10.1016/j.ypmed.2011.08.017
  11. McCusker SM, Macqueen I, Lough G, MacDonald AI, Campbell C, Graham SV. Gaps in detailed knowledge of human papillomavirus (HPV) and the HPV vaccine among medical students in Scotland. BMC Public Health 2013; 13: 264. DOI: https://doi.org/10.1186/1471-2458-13-264
  12. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). (2010).
  13. Anil KC. Beyond cervical cancer: Burden of other HPV-related cancers among men and women. Journal of Adolescent Health 2010; 46:20- 26 DOI: https://doi.org/10.1016/j.jadohealth.2010.01.016
  14. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl. 3): S3/26–34.. DOI: https://doi.org/10.1016/j.vaccine.2006.05.026
  15. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol. 2005;32(Suppl. 1): S82–90. DOI: https://doi.org/10.1016/j.jcv.2004.10.020
  16. Knowles S. & Parker M. Female Genital Cancer in Kosovo; a situational analysis of breast and cervical cancer. UNFPA 2008.
  17. Wolniewicz E. Cervical cancer - knowledge, prevention and exposure to risk factors among students from various countries. Presented at the ISGE World Congress 2016, Volume: 32, Orlando, USA.
  18. Centers for Disease Control and Prevention (CDC). Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60: 1705–1708.
  19. Human papillomavirus vaccines. WHO position paper, May 2017.Wkly Epidemiol Rec 2017;92(19):241–68.
  20. HPV vaccination: What Everyone should know [Internet]. Cdc.gov. 2022 [cited 2022 Mar 26]. Available from: https://www.cdc.gov/vaccines/vpd/hpv/public/index.html
  21. Garbutt JM, Dodd S, Walling E, Lee AA, Kulka K, Lobb R. Barriers and facilitators to HPV vaccination in primary care practices: a mixed methods study using the Consolidated Framework for Implementation Research. BMC family practice 2018;19(1):53. DOI: https://doi.org/10.1186/s12875-018-0750-5
  22. Scientific Committee on Vaccine Preventable Diseases. Recommendation on the use of human papillomavirus (HPV) vaccine. Hong Kong: Department of Health; 2013 Mar [accessed 2017 Jul 30].
  23. Department of Health. Fact sheet on human papillomavirus (HPV) vaccine for health care professionals. Hong Kong: Department of Health; 2007 Mar 20 [accessed 2017 Jul 30.
  24. Venezuela RF, Monetti MS, Kiguen AX, Frutos MC, Mosmann JP, Cuffini CG. Knowledge of the general community in Cordoba, Argentina, on Human Papilloma Virus Infection and its prevention. Asian Pac J Cancer Prev 2016;17(5):2689–94.
  25. Juedin P, Liveright E, Carmen M, Perkins R. Race, ethnicity and income as factors for HPV vaccine acceptance and use. Human Vaccines &Immunotherapeutics. 2013; 9(7):1413-1420. DOI: https://doi.org/10.4161/hv.24422
  26. Young J, Bernheim R, Korte J, et al. Human papillomavirus vaccination recommendation may be linked to reimbursement: a survey of Virginia family practitioners and gynecologists. Journal of Pediatric & Adolescent Gynecology. 2011; 24:380–5. DOI: https://doi.org/10.1016/j.jpag.2011.06.016
  27. HPV also known as human papillomavirus. Centers for Disease Control and Prevention Website. https://www.cdc.gov/vaccines/parents/diseases/teen/hpv-indepth-color.pdf. Updated July 2015. Accessed December 29, 2016.
  28. Hendry M, Lewis R, Clements A, Damery S, Wilkinson C. HPV? Never heard of it!: a systematic review of girls’ and parents’ information, views and preferences about human papillomavirus vaccination. Vaccine. 2013; 31(45):5152-5167. DOI: https://doi.org/10.1016/j.vaccine.2013.08.091
  29. Trim K, Nagji N, Elit L, Roy K. Parental knowledge, attitudes, and behaviors toward human papillomaviruses vaccination for their children: a systematic review from 2001 to 2011. Obstetrics and Gynecology International. 2012; 2012:1-12. doi:10.1155/2012/921236. DOI: https://doi.org/10.1155/2012/921236
  30. Bianco A, Pileggi C, Iozzo F, Nobile CG, Pavia M. Vaccination against human papilloma virus infection in male adolescents: knowledge, attitudes, and acceptability among parents in Italy. Human Vaccines &Immunotherapeutics. 2014 Sep 2;10(9):2536–42. DOI: https://doi.org/10.4161/21645515.2014.969614
  31. Napolitano F, Napolitano P, Liguori G, Angelillo IF. Human papillomavirus infection and vaccination: Knowledge and attitudes among young males in Italy. Human Vaccines &Immunotherapeutics. 2016 Jun 2;12(6):1504–10. DOI: https://doi.org/10.1080/21645515.2016.1156271
  32. Di Giuseppe G, Abbate R, Liguori G, Albano L, Angelillo IF. Human papillomavirus and vaccination: Knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. British journal of cancer 2008;99(2):225–9. DOI: https://doi.org/10.1038/sj.bjc.6604454
  33. Venezuela RF, Monetti MS, Kiguen AX, Frutos MC, Mosmann JP, Cuffini CG. Knowledge of the general community in cordoba, argentina, on human papilloma virus infection and its prevention. Asian Pac J Cancer Prev. 2016;17(5):2689–94.
  34. Isidean S, Tota J, Gagnon J, Franco E. Human papillomavirus vaccines: key factors in planning cost effective vaccination programs. Expert Review Vaccines. 2014:1-15. DOI: https://doi.org/10.1586/14760584.2015.964213
  35. National Institutes of Health Website. Recurrent respiratory papillomatosis or laryngeal papillomatosis. http://www.nidcd.nih.gov/health/voice/pages/laryngeal.aspx. Updated April 1, 2011. Accessed December 29, 2016.
  36. Wong K, Do Y. Are there socioeconomic disparities in women having discussions on human papillomavirus vaccine with health care providers? BioMed Central Women’s Health 2012; 12(33):1-7. DOI: https://doi.org/10.1186/1472-6874-12-33
  37. Ge S, Gong B, Cai X, Yang X, Gan X, Tong X, et al. Prevent cervical cancer by screening with reliable human papillomavirus detection and genotyping. Cancer Medicine 2012;1(1):59-67. DOI: https://doi.org/10.1002/cam4.9
  38. Ryser M, McGoff K, Herzog D, Sivakoff D, Myer E. Impact of coverage dependent marginal costs on optimal HPV vaccination strategies. Epidemics 2015; 11:32-47. DOI: https://doi.org/10.1016/j.epidem.2015.01.003